Johnson & Johnson is looking to sell its Cerenovus stroke therapy business, according three unnamed people "with knowledge of ...

The global joint replacement devices market, valued at US$22.50 billion in 2023, is forecasted to grow at a robust CAGR of 4.8%, reaching US$23.42 ...

The global joint replacement devices market, valued at US$22.50 billion in 2023, is forecasted to grow at a robust CAGR of 4.8%, reaching US$23.42 billion in 2024 and an impressive US$31.09 billion by ...

Johnson & Johnson MedTech (NYSE: JNJ) announced today that it launched the CereGlide 92 catheter system for treating acute ...

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

Johnson & Johnson is putting its stroke care business up for sale as the company aims to reorganize and rebuild its medtech unit, the ...

Johnson & Johnson (NYSE:JNJ) has put its stroke care business up for sale, aiming for a valuation of more than $1B, the Financial Times reported on Tuesday, citing people familiar with the matter.

New e-book explores transformative medtech advancements in pulsed field ablation for ... gained regulatory approvals around the world and even more began clinical trials in 2024. While Johnson & ...

The Clarivate e-book highlights new medtech breakthroughs in the pulsed field ablation (PFA) market, forecasting its future ...

Barclays raised the firm’s price target on Johnson & Johnson to $166 from $159 and keeps an Equal Weight rating on the shares. The company ...